Abstract | BACKGROUND: METHODS: The authors prospectively evaluated 15 consecutive cancer patients during the conversion from IV to transdermal fentanyl. In all patients, a transdermal patch delivering fentanyl at a rate equivalent to that of the final continuous IV infusion was applied. The CII rate was decreased by 50% 6 hours after application of the fentanyl patch and then discontinued after another 6 hours. Demand boluses of IV fentanyl equivalent in dosage to 50-100% of the final CII rate remained available via PCA during the 24 hours after patch application. Pain intensity (on a scale of 0-10), sedation (on a scale of 0-3), and hourly PCA administration (microg/hr) were assessed and recorded immediately prior to application of the fentanyl patch and 6, 12, 18, and 24 hours thereafter. RESULTS:
Pain intensity, sedation, and hourly PCA administration appeared to remain stable throughout the transition from IV to transdermal fentanyl. CONCLUSIONS: The results of the current study demonstrate that the conversion from IV to transdermal fentanyl can be accomplished safely and effectively using a 1:1 (IV:transdermal) conversion ratio and a two-step taper of the CII over 12 hours.
|
Authors | C A Kornick, J Santiago-Palma, N Khojainova, L H Primavera, R Payne, P L Manfredi |
Journal | Cancer
(Cancer)
Vol. 92
Issue 12
Pg. 3056-61
(Dec 15 2001)
ISSN: 0008-543X [Print] United States |
PMID | 11753984
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
|
Copyright | Copyright 2001 American Cancer Society. |
Chemical References |
- Analgesics, Opioid
- Fentanyl
|
Topics |
- Administration, Cutaneous
- Adult
- Aged
- Analgesics, Opioid
(administration & dosage, pharmacology)
- Female
- Fentanyl
(administration & dosage, pharmacology)
- Humans
- Infusions, Intravenous
- Male
- Middle Aged
- Neoplasms
(complications)
- Pain
(drug therapy)
- Prospective Studies
|